Skydance Vascular Wins U.S. Patent Allowance for Retractable Needle Catheter Delivery System

Skydance Vascular said the U.S. Patent and Trademark Office allowed all 15 claims in a patent application covering a retractable needle catheter delivery apparatus with side-port tubing. The allowance expands the company’s intellectual property portfolio across the U.S., Europe and Japan as it pushes commercialization of its Osprey platform.

Why it matters: - The allowance gives Skydance Vascular additional patent protection around its core catheter delivery technology. - The decision strengthens the company’s position as it scales commercialization of the Osprey platform. - The portfolio now spans seven granted and allowed patents across the U.S., Europe and Japan.

What happened: - The U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 18/362,622, titled "Retractable Needle Catheter Delivery Apparatus." - The USPTO allowed all 15 claims without modification. - The announcement was made Sept. 22, 2026, in Delray Beach, Florida.

The details: - The allowed claims cover an integrated catheter insertion device with the catheter housed inside and advanced through a needle that fully retracts into the device housing. - The claims also cover a proximal connector with an angled side port that advances the catheter tip past the needle. - In the reasons for allowance, the patent examiner said none of more than 20 prior art references disclosed or suggested the claimed combination. - The application expands Skydance Vascular’s Retractable Needle Catheter Delivery Apparatus with Side Port Tubing family. - A counterpart patent has already been issued in Europe, and a related application is under examination in Japan. - Skydance Vascular said its intellectual property estate now includes seven granted patents and allowed applications across the United States, Europe and Japan. - The company said it has four additional pending applications across the U.S., Europe, Japan and the Patent Cooperation Treaty. - The portfolio includes three patent families. - The first family, Retractable Needle Catheter Delivery Apparatus, covers the company’s "through the needle" catheter delivery system with full needle retraction. - That family includes U.S. Patent Nos. 11,197,980, 11,529,498 and 12,496,434, plus two granted Japanese patents and pending applications in the U.S. and Europe. - The second family, Retractable Needle Catheter Delivery Apparatus with Side Port Tubing, adds side-port delivery channels. - That family includes the newly allowed U.S. application, a granted European patent and an active Japanese application. - The third family, Next-Generation Catheter Delivery Enhancements, covers mechanical refinements including a needle-retraction countdown mechanism, blood magnification features, advanced seals and targeted fluid-flow controls. - That third family is published internationally as WO 2026/096249 and remains pending under the Patent Cooperation Treaty. - Bill Bold, CEO of Skydance Vascular, said the allowance strengthens the proprietary foundation of the Osprey platform and supports the company’s commercial strategy. - Michael Anstett, RN, founder and chief clinical officer, said integrating an angled side port into a fully retractable system solved a mechanical challenge without adding bulk or compromising safety mechanisms. - Anstett said the examiner’s decision confirms the company’s approach takes a different engineering path than legacy devices.

Between the lines: - The allowance suggests the USPTO saw meaningful novelty in combining full needle retraction with an integrated side-port connector. - The fact that the examiner cited more than 20 prior art references underscores how crowded the catheter-delivery patent space can be. - The broader portfolio shows Skydance Vascular is trying to build layered protection around both the base platform and follow-on refinements.

What’s next: - Skydance Vascular will continue pursuing patents in Europe, Japan, the U.S. and the PCT system. - The company said it will keep developing future products as commercialization of the Osprey platform advances. - The newly allowed U.S. application still needs formal patent issuance before becoming a granted patent.

The bottom line: - Skydance Vascular added another key U.S. patent win around its retractable needle catheter design, reinforcing a global IP strategy built to protect the Osprey platform.